Arrowhead and Takeda reveal mixed new fazirsiran data

9 January 2023
arrowhead-company

Today, US biotech Arrowhead Pharmaceuticals (Nasdaq: ARWR) announced positive top-line data from a Phase II placebo-controlled study evaluating an investigational RNAi therapeutic, fazirsiran (TAK-999/ARO-AAT), for the treatment of alpha-1 antitrypsin (AATD) liver disease. These were described as “positive,” but investor reaction was negative, with the firm’s share price falling 20% to $30.92.

The drug is being developed with Japan’s Takeda Pharmaceuticals (TYO: 4502), under a 2020 collaboration that provided Arrowhead with $300 million upfront and eligibility for $740 million more in milestone payments.

AATD is a rare genetic disorder estimated to affect 1 in 3,000-5,000 people in the USA. While a third of patients develop liver disease, the only current treatment option is transplantation.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology